Related Experiment Video

Updated: Aug 9, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

[Clinical pharmacology and efficacy of meropenem]

H Tsutsumi1, S Chiba

  • 1Department of Pediatrics, Sapporo Medical College.

The Japanese Journal of Antibiotics
|June 1, 1992
PubMed

Insights

Meropenem (MEPM), a new carbapenem antibiotic, shows promising pharmacokinetic and clinical profiles in pediatric patients. It demonstrated effective bacterial eradication with minimal adverse effects, suggesting its potential for treating pediatric infections.

Area of Science:

  • Pharmacology
  • Pediatric Infectious Diseases
  • Antimicrobial Agents

Background:

  • Meropenem (MEPM) is a novel carbapenem antibiotic.
  • Pediatric infections require effective and safe antimicrobial treatments.

Purpose of the Study:

  • To evaluate the pharmacokinetics of meropenem (MEPM) in pediatric patients.
  • To assess the clinical efficacy and safety of meropenem (MEPM) for treating bacterial infections in children.

Main Methods:

  • Pharmacokinetic analysis of MEPM in 3 pediatric patients via intravenous drip infusion (16-22 mg/kg).
  • Serum and urine concentrations of MEPM were determined using bioassay.
  • Clinical evaluation of MEPM in 14 pediatric patients (1 month to 14 years) with various bacterial infections.

Main Results:

  • Average peak serum MEPM level was 38.4 µg/ml with a T1/2 beta of 1.26 hours.
  • Urinary recovery rate for MEPM was 65.6% within 6 hours post-administration.
  • Excellent/good clinical response in all patients; bacteriological eradication in 7/8 cases. Mild, transient elevations in GOT/GPT observed in 2 patients.

Conclusions:

  • Meropenem (MEPM) exhibits favorable pharmacokinetic properties in pediatric patients.
  • MEPM demonstrated high clinical efficacy and a good safety profile for treating pediatric bacterial infections.
  • Further investigation into MEPM's role in pediatric infectious disease management is warranted.

More Related Videos

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method12:03

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method

Published on: April 18, 2019

Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression08:58

Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression

Published on: April 18, 2025

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration01:23

Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration

Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s half-life.
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...